Solvonis Therapeutics plc
SVNS.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -£1,590 | -£3,120 | -£2,705 | -£954 |
| Dep. & Amort. | £0 | £177 | £113 | £46 |
| Deferred Tax | £0 | £0 | -£1,724 | £0 |
| Stock-Based Comp. | £317 | £369 | £858 | £0 |
| Change in WC | -£27 | £413 | -£640 | £646 |
| Other Non-Cash | £170 | £923 | £1,738 | -£546 |
| Operating Cash Flow | -£1,130 | -£1,238 | -£2,360 | -£254 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -£4 | -£232 | -£718 | -£1 |
| Net Acquisitions | -£13 | £0 | £0 | £0 |
| Inv. Purchases | £0 | £0 | £0 | £0 |
| Inv. Sales/Matur. | £0 | £0 | £0 | £0 |
| Other Inv. Act. | -£320 | £0 | £0 | £0 |
| Investing Cash Flow | -£337 | -£232 | -£718 | -£1 |
| Financing Activities | – | – | – | – |
| Debt Repay. | £200 | £0 | £0 | £0 |
| Stock Issued | £1,924 | £0 | £4,475 | £500 |
| Stock Repurch. | £0 | £0 | £0 | £0 |
| Dividends Paid | £0 | £0 | £0 | £0 |
| Other Fin. Act. | -£41 | £0 | -£340 | £800 |
| Financing Cash Flow | £2,083 | £0 | £4,135 | £800 |
| Forex Effect | -£14 | -£15 | -£15 | £24 |
| Net Chg. in Cash | £602 | -£1,485 | £1,042 | £389 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | £155 | £1,640 | £598 | £209 |
| End Cash | £757 | £155 | £1,640 | £598 |
| Free Cash Flow | -£1,134 | -£1,470 | -£3,078 | -£255 |